---
title: "Cardiomyocyte-Derived Cell-Free DNA Detected in Hypertrophic Cardiomyopathy Patients"
id: "medrxiv-7-cardiomyocyte-derived-cell-free-dna-in-hypertrophic-cardiomyopathy"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-cardiomyocyte-derived-cell-free-dna-in-hypertrophic-cardiomyopathy"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.12.26365358v1?rss=1"
published_at: "2026-10-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cardiomyocyte-Derived Cell-Free DNA Detected in Hypertrophic Cardiomyopathy Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-cardiomyocyte-derived-cell-free-dna-in-hypertrophic-cardiomyopathy
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.12.26365358v1?rss=1)
- **Published At:** 2026-10-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators measured plasma **cell-free DNA** (cfDNA) and cardiomyocyte-derived cfDNA (cfDNA-CM) in 57 stable hypertrophic cardiomyopathy (HCM) patients and 10 acute myocardial infarction (AMI) controls using whole genome bisulfite sequencing and methylation-based tissue deconvolution. - The assay produced higher total cfDNA and higher cfDNA-CM fractions in AMI controls versus HCM, which the authors interpreted as assay validity evidence. - Median cfDNA yield within the HCM cohort was reported as 12.22 ng (IQR: 7.77, 18.94); cfDNA-CM fraction in HCM samples ranged from 0% to 6.4% of total cfDNA. - Patients in higher cfDNA-CM tertiles had higher body mass index (BMI) (p=0.001), greater prevalence of BMI ≥30 kg/m2 (p<0.001), and higher prevalence of obstructive sleep apnea (p=0.038). - No significant differences across cfDNA-CM tertiles were observed for most demographic, genetic, or laboratory features; NT-proBNP and troponin levels did not differ across tertiles (p=0.83 and p=0.29). - Higher cfDNA-CM tertile was numerically associated with worse New York Heart Association (NYHA) functional class and presence of left ventricular outflow tract (LVOT) obstruction, though statistical significance was not reported for these comparisons. - Authors concluded that isolation and quantification of cfDNA and detection of **cardiomyocyte-derived cfDNA** in chronic stable HCM patients are feasible and that cfDNA-CM correlates with cardiometabolic comorbidity burden rather than traditional circulating biomarkers. - The source did not provide detailed methodological parameters for library preparation beyond WGBS or specific patient demographics beyond the reported associations; data access is restricted due to patient privacy but anonymized subsets may be available on request under data-use agreement and IRB approval.
## Clinical Analysis & Structured Key Points
Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy | medRxiv Skip to main content Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy View ORCID Profile Daniel Kamna , Brett A Davis , Cora Layman , Jack Wiedrick , Sammantha Avaylon , Kandace Wheeler , Israt Jahan , Lucia Carbone , View ORCID Profile Ahmad Masri doi: https://doi.org/10.64898/2026.10.12.26365358 Daniel Kamna 1 Oregon Health & Science University Knight Cardiovascular Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Daniel Kamna Brett A Davis 2 Oregon Health & Science University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cora Layman 1 Oregon Health & Science University Knight Cardiovascular Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jack Wiedrick 3 Oregon Health & Science University School of Medicine, UNITED STATES Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sammantha Avaylon 1 Oregon Health & Science University Knight Cardiovascular Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kandace Wheeler 1 Oregon Health & Science University Knight Cardiovascular Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Israt Jahan 1 Oregon Health & Science University Knight Cardiovascular Institute, UNITED STATES; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lucia Carbone 2 Oregon Health & Science University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ahmad Masri 2 Oregon Health & Science University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ahmad Masri For correspondence: masria{at}ohsu.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Introduction: In hypertrophic cardiomyopathy (HCM), wall stress and subclinical myocardial injury related in part to pathological hypercontractility, which in turn are associated with worse outcomes. Cell-free DNA (cfDNA) is released from cardiomyocytes (cfDNA-CM) through irreversible cellular injury and death. We investigated the feasibility of quantifying cfDNA-CM and its relationship to HCM patient characteristics. Methods: We analyzed 57 plasma samples from stable patients with HCM and 10 plasma samples from patients with acute myocardial infarction (AMI). Plasma cfDNA was isolated from both groups. Whole genome bisulfite sequencing (WGBS) libraries were generated and sequenced with short-read sequencing. Methylation patterns were used for tissue deconvolution analysis and cell-specific cfDNA quantification. Results: Yields of cfDNA (p = 0.003) and cfDNA-CM (p = 0.002) fractions were higher in AMI controls than HCM, supporting the validity of the assay. Within the HCM cohort, the median cfDNA yield was 12.22 ng [IQR: 7.77, 18.94]. The cfDNA-CM fraction in this cohort ranged from 0% to 6.4% of total cfDNA. Higher cfDNA-CM tertiles were associated with higher body mass index (BMI, p=0.001), a greater prevalence of BMI 30 kg/m2 (p<0.001), and a higher prevalence of obstructive sleep apnea (p=0.038). No significant differences were observed in other demographic, genetic, and laboratory characteristics. Higher cfDNA-CM tertile was numerically associated with higher New York Heart Association (NYHA) functional class and left ventricular outflow tract (LVOT) obstruction, while circulating biomarkers of wall stress (NT-proBNP) and myocardial injury (troponin) did not differ across tertiles (p=0.83 and p=0.29, respectively). Conclusion: Isolation and quantification of cfDNA as well as detection of cfDNA-CM in chronic stable patients with HCM are feasible. Higher cfDNA-CM fraction was associated with increasing BMI and cardiometabolic comorbidity burden. The absence of association with traditional circulating biomarkers suggests that cfDNA-CM may reflect a distinct domain of myocardial health, injury, and adverse remodeling. Competing Interest Statement The authors have declared no competing interest. Clinical Trial NA Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: OHSU IRB I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data underlying this article cannot be shared publicly due to privacy and ethical restrictions (patient confidentiality). Anonymized data subsets may be made available from the corresponding author upon reasonable request and subject to a data-use agreement and institutional review board approval. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 13, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy Daniel Kamna , Brett A Davis , Cora Layman , Jack Wiedrick , Sammantha Avaylon , Kandace Wheeler , Israt Jahan , Lucia Carbone , Ahmad Masri medRxiv 2026.10.12.26365358; doi: https://doi.org/10.64898/2026.10.12.26365358 Share This Article: Copy Citation Tools Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy Daniel Kamna , Brett A Davis , Cora Layman , Jack Wiedrick , Sammantha Avaylon , Kandace Wheeler , Israt Jahan , Lucia Carbone , Ahmad Masri medRxiv 2026.10.12.26365358; doi: https://doi.org/10.64898/2026.10.12.26365358 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4918) Dentistry and Oral Medicine (487) Dermatology (421) Emergency Medicine (666) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1654) Epidemiology (16111) Forensic Medicine (35) Gastroenterology (1224) Genetic and Genomic Medicine (7160) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5177) Health Policy (1452) Health Systems and Quality Improvement (1804) Hematology (594) HIV/AIDS (1361) Infectious Diseases (except HIV/AIDS) (16391) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7431) Nursing (372) Nutrition (1108) Obstetrics and Gynecology (1271) Occupational and Environmental Health (1018) Oncology (3681) Ophthalmology (1076) Orthopedics (400) Otolaryngology (460) Pain Medicine (487) Palliative Medicine (142) Pathology (714) Pediatrics (1833) Pharmacology and Therapeutics (742) Primary Care Research (780) Psychiatry and Clinical Psychology (6024) Public and Global Health (9877) Radiology and Imaging (2476) Rehabilitation Medicine and Physical Therapy (1491) Respiratory Medicine (1257) Rheumatology (653) Sexual and Reproductive Health (791) Sports Medicine (590) Surgery (790) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Psychosocial profile in adults with congenital heart disease by documented anxiety disorder history](https://medichelpline.com/clinical-feed/plos-one-21-psychosocial-profile-of-adults-with-congenital-heart-disease-according-to.md)
- [Cardiovascular risk prediction models in women: protocol for an updated systematic review](https://medichelpline.com/clinical-feed/plos-one-7-cardiovascular-risk-prediction-models-for-women-a-systematic-review-protocol.md)
- [Ascending Aortic Calcium Predicts Risk in Patients with Normal PET Perfusion, Flow and CAC](https://medichelpline.com/clinical-feed/medrxiv-18-ascending-aortic-calcium-identifies-patients-at-risk-despite-normal-myocardial.md)
- [Plethysmometry: automated cuff method to estimate systolic, diastolic and mean arterial pressure r](https://medichelpline.com/clinical-feed/medrxiv-4-plethysmometry-an-automated-cuff-based-method-for-estimating-ranges-of-systolic.md)
- [Long-term cardiovascular risk after assisted reproductive technology and infertility: nationwide c](https://medichelpline.com/clinical-feed/plos-medicine-0-long-term-risk-of-cardiovascular-disease-after-assisted-reproductive-technology.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.